Close Menu

lawsuit

Life Tech claims that Biosearch is infringing one or more claims of a patent related to oligonucleotide PCR probes by manufacturing and selling its BHQplus probes for quantitative PCR applications.

An article about an acquisition topped the list of the most-read stories for the year on GenomeWeb Daily News, while restructurings, lawsuits, and one firm's IPO plans made it into the top 10.

The suit centers on methods of testing for canine breed identification.

In a ruling last week, a District Court judge adopted Life Tech's constructions for the vast majority of terms where the plaintiff and the defendant offered different interpretations.

The judge dismissed the case centered on array technologies saying Illumina's argument for infringement "does not make any sense."

The SEC alleges the two individuals traded shares of the two firms after receiving insider information about Sequenom's unsuccessful bid to acquire Exact Sciences in 2009 and Sequenom's mishandling of data on its Down syndrome test.

The new allegations are an attempt by CSHL to delay a ruling on the dismissal of the lawsuit so that it can review certain RNAi companies' confidential materials, the law firm alleged.

Collier County's Board of County Commissioners is asking a state judge to declare The Jackson Laboratory's plan a "valid public purpose" allowing for $130 million in promised county bonds. But the board's use of an arbitrator to decide a land use issue has sparked a separate lawsuit.

CSHL specifically names Arrowhead Research subsidiaries Calando Pharmaceuticals and Insert Therapeutics, which were merged into one firm under the Calando name in 2008, and RXi Pharmaceuticals.

Starting last year, PacBio "conspired with defendant employees of Affymetrix" to hire employees from Affy, and then gathered confidential information on Affy in order to gain an "unfair economic advantage," Affy alleged in its complaint.

Pages

Italy has held talks with vaccine developers to manufacture mRNA-based SARS-CoV-2 vaccines, according to the Financial Times.

The Associated Press reports US officials are removing restrictions on fetal tissue research that were added during the Trump Administration.

The Biden Administration is investing $1.7 billion to detect and monitor SARS-CoV-2 variants.

In PLOS this week: genome instability in Aicardi-Goutières Syndrome, introduction of SARS-CoV-2 to the Colombian Amazon, and more.